Search

Displaying results 9421 - 9430 of 9613 in total
  1. Drug

    Frespaciguat

    go.drugbank.com/drugs/DB21683
    Investigational

    Frespaciguat has a monoisotopic molecular weight of 608.14 Da.

  2. Drug

    Galactose-uridine-5'-diphosphate

    go.drugbank.com/drugs/DB03501
    Experimental

    Serves as a source of galactose in the synthesis of lipopolysaccharides, cerebrosides, and lactose.

  3. Drug

    MVA-SARS-2-S

    go.drugbank.com/drugs/DB16432
    Investigational

    MVA is a highly attenuated poxvirus vector[A226603] that has a high-level of biological safety due to its quality of being a non-replicating virus in mammalian hosts[L30458] and is used to develop vaccines

  4. Drug

    Flizasertib

    go.drugbank.com/drugs/DB21613
    Investigational

    Flizasertib has a monoisotopic molecular weight of 271.11 Da.

  5. Drug

    CoVac-1

    go.drugbank.com/drugs/DB16429
    Investigational

    T-cell immunity[A226588]. … Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein[A226588].

  6. Drug

    Bezisterim

    go.drugbank.com/drugs/DB05212
    Investigational

  7. Drug

    Doramectin

    go.drugbank.com/drugs/DB11400
    ExperimentalVet approved

    Doramectin is a veterinary drug approved by the Food and Drug Administration for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites

  8. Drug

    Tersolisib

    go.drugbank.com/drugs/DB21752
    Investigational

    STX-478 is under investigation in clinical trail NCT05768139 (First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  9. Drug

    Ronacaleret

    go.drugbank.com/drugs/DB05255
    Investigational

    Ronacaleret is a calcium-sensing receptor antagonist.

  10. Drug

    Talnetant

    go.drugbank.com/drugs/DB06429
    Investigational

    Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential